Cidara Therapeutics, Inc.
https://www.cidara.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cidara Therapeutics, Inc.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 2: COVID-19 Shock Waves And Silver Linings
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
Antifungal Drug Sponsors Seek Clearer Regulatory Pathway, Less Burdensome Trials
Citing difficulties in conducting randomized trials, industry speakers call for a new way of thinking about the US FDA's substantial evidence standard for antifungal approvals under the LPAD route, as well as revisions to enrollment criteria and study endpoints.
Scrip Asks…What Does 2020 Hold For Biopharma? Part 3: Policy And Regulation
The US election will intensify the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals